network member

Vanderbilt-Ingram Cancer Center

691 Preston Building Nashville, TN 37232

About Network Member

Vanderbilt-Ingram Cancer Center provides compassionate care, evidence-based prevention, pioneering research, community engagement and survivorship support. Designated a Comprehensive Cancer Center by the National Cancer Institute and a member of the National Comprehensive Cancer Network, Vanderbilt-Ingram is at the forefront of discovery. Our teams of scientists and clinicians are defining personalized care with immunotherapies, targeted treatments, precision radiation-oncology, innovative surgeries, and novel imaging technologies. Website: Vanderbilt-Ingram Cancer Center

https://www.vicc.org/

800-811-8480

Enrollment Closed

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Deepak Kilari

Cancer areas:Bladder

Froedtert & the Medical College of Wisconsin

John Theurer Cancer Center at Hackensack Meridian Health

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University of Rochester Medical Center - Wilmot Cancer Institute

Vanderbilt-Ingram Cancer Center

Virginia Commonwealth University

See clinicaltrials.gov

Currently Enrolling

TBCRC046

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Angela DeMichele

Cancer areas:Breast

Dana-Farber Cancer Institute

Fred Hutchinson Cancer Research Center

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Penn Medicine Abramson Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Mayo Clinic

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

University of Alabama at Birmingham Comprehensive Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

Matthew D. Galsky

Cancer areas:Bladder Urothelial Carcinoma

Huntsman Cancer Institute at the University of Utah

Icahn School of Medicine at Mount Sinai

Rutgers Cancer Institute of New Jersey

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Study Completed

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

UPMC Hillman Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov